Nature, the world’s premiere science journal, has finally caught on to what Rainbow Coral Corp. (OTCBB: RBCC) has known for some time: The cell-growth technology pioneered by RBCC partner n3D Biosciences has the potential to completely revolutionize cellular research.
n3D’s magnetic levitation technology was the subject of a feature article in the journal’s April issue titled “A Better Brew.” The system allows researchers at university laboratories and pharmaceutical companies to grow three-dimensional, lifelike microtissues similar enough to those found within the body to be used in in vivo drug-testing models. RBCC signed a joint venture agreement to help market and develop the technology last year.
The abstract of the article is available now at n3D’s website http://www.n3dbio.com/a-better-brew-nature-technology-review-on-cell-culture/.
The high-profile feature is certain to spread the word on n3D’s groundbreaking magnetic levitation system to labs across the globe at a time when researchers are eagerly adopting and evaluating 3-D cell-growth formats, says RBCC CEO Patrick Brown.
“We strongly believe that n3D’s levitation technology is the future of cellular research,” Brown said. “We anticipate an explosion of interest in the company and its products as a result of this terrific Nature article.”
Rainbow BioSciences, RBCC’s biotech division, signed a joint venture agreement with n3D last year to help develop and market the Bio-Assembler. For more information on this and other biotech initiatives, please visit www.rainbowbiosciences.com/investors.html.
Rainbow BioSciences will develop new medical and research technology innovations to compete alongside companies such as Bristol Myers Squibb Co. (NYSE: BMY), Biogen Idec Inc. (NASDAQ: BIIB), Abbott Laboratories (NYSE: ABT) and Amgen Inc. (NASDAQ: AMGN).
About Rainbow BioSciences
Rainbow BioSciences, LLC, is a wholly owned subsidiary of Rainbow Coral Corp. (OTCBB: RBCC). The Company continually seeks out new partnerships with biotechnology developers to deliver profitable new medical technologies and innovations. For more information on our growth-oriented business initiatives, please visit www.RainbowBioSciences.com. For investment information and performance data on the Company, please visit www.RainbowBioSciences.com/investors.html.
Notice Regarding Forward-Looking Statements
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words "believes," "expects," "anticipate" or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from those expressed or implied by such forward-looking statements. In addition, description of anyone's past success, either financial or strategic, is no guarantee of future success. This news release speaks as of the date first set forth above and the Company assumes no responsibility to update the information included herein for events occurring after the date hereof.
Patrick Brown, 850-269-7230
President and CEO
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Press Release Service provided by PRConnect.
Stock quotes supplied by Telekurs USA
Postage Rates Bots go here